Hilton Head Capital Partners, LLC
Position in GALT — Galectin Therapeutics Inc
CIK 2109913
HILTON HEAD ISLAND, SC
Position in GALT
as of Mar 31, 2026
· filed Apr 20, 2026
Position Value
$2,232
-$1,096 QoQ
Shares Held
800
0.0% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in GALT Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Hilton Head Capital Partners, LLC holds $387,863 across 30 Biotechnology names. GALT ranks #21 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TRVI |
Trevi Therapeutics, Inc.
|
4,250 | $50,702 | |
| 2 | BBIO |
BridgeBio Pharma, Inc.
|
650 | $48,269 | |
| 3 | OCUL |
Ocular Therapeutix, Inc
|
4,520 | $38,284 | |
| 4 | SRRK |
Scholar Rock Holding Corp
|
683 | $33,576 | |
| 5 | TYRA |
Tyra Biosciences, Inc.
|
772 | $29,567 | |
| 6 | IONS |
Ionis Pharmaceuticals Inc
|
353 | $26,506 | |
| 7 | DYN |
Dyne Therapeutics, Inc.
|
1,446 | $26,215 | |
| 8 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
50 | $22,327 |
All Filings in GALT
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,232 | 800 | Shares | Sole | 2026-04-20 | |
| 2025-12-31 | $3,328 | 800 | Shares | Sole | 2026-02-11 | |
| No filing history on record for this holder in this stock. | ||||||